Frequencies for first 10,000 rows of lit_ref variable in demo2018q1 dataset : Literature Reference | Freq. Percent Cum. ----------------------------------------+----------------------------------- | 9,483 94.83 94.83 , AMAYA-CHANAGA C, LUJAN J, CHOI M, M.. | 1 0.01 94.84 , ANTONIOTTI C, LONARDI S, APRILE G, .. | 1 0.01 94.85 , BARONE D, SCARPI E, OBOLDI D, AMADO.. | 1 0.01 94.86 , BARONE D, SCARPI E, OBOLDI D, AMADO.. | 1 0.01 94.87 , BLANCHO G, VILLE S, MORELON E, BAMO.. | 1 0.01 94.88 , BORTLICEK Z, CAMPR V, KOPALOVA N, B.. | 1 0.01 94.89 , BUCKSTEIN R, NANCY P, WEERASINGHE R.. | 1 0.01 94.90 , COILLY A, ROSSIGNOL E, FOUGEROU-LEU.. | 1 0.01 94.91 , DESJARDINS A, MASON W, KESARI S, MA.. | 1 0.01 94.92 , DUBEAU T, SEVERNS P, GUSTINE J, GHO.. | 1 0.01 94.93 , DUBEAU T, SEVERNS P, GUSTINE J, GHO.. | 1 0.01 94.94 , DUECK A, ANSELL S, GANO K, CONLEY C.. | 1 0.01 94.95 , ELBAZ T, EL RAZIKY M, GOMAA A, ABOU.. | 1 0.01 94.96 , ET AL. CLINICAL IMPACT OF BAALC EXP.. | 1 0.01 94.97 , FERRARI A, MANNI M, DONDI A, CHIARE.. | 1 0.01 94.98 , FOWLER N, PINA-OVIEDO S, MEDEIROS L.. | 1 0.01 94.99 , FOWLER N, PINA-OVIEDO S, MEDEIROS L.. | 3 0.03 95.02 , FOX C, BODEN A, BLOOR A, DUNGAWALLA.. | 1 0.01 95.03 , FOX C, BODEN A, BLOOR A, DUNGAWALLA.. | 1 0.01 95.04 , HAMADA S, KUROE A, TSUKINO M. DOES .. | 1 0.01 95.05 , HUANG H, SAMOILOVA O, BELCH A, FARB.. | 3 0.03 95.08 , HUANG H, SAMOILOVA O, BELCH A, FARB.. | 5 0.05 95.13 , IM S, GUO M, MARME F SUBGROUP ANALY.. | 1 0.01 95.14 , JABBOUR E, LEDESMA C, KORBLING M, A.. | 2 0.02 95.16 , JANSSEN-HEIJNEN M, CREEMERS G, PRUI.. | 1 0.01 95.17 , KAMIYA K, MAEKAWA T, KOMINE M, MURA.. | 1 0.01 95.18 , KITO Y, IZAWA N, TSUDA T, MORITA S,.. | 1 0.01 95.19 , KOJIMA Y, MIYAZAWA K, MATSUMOTO S, .. | 1 0.01 95.20 , KOLSTAD A, JERKEMAN M, RATY R, LAUR.. | 1 0.01 95.21 , LEE J, URBA S, AND WORDEN F A PHASE.. | 1 0.01 95.22 , LEE J, URBA S, AND WORDEN F A PHASE.. | 1 0.01 95.23 , LEWIS L AND BROWN J. FINAL FOLLOW-U.. | 1 0.01 95.24 , LI H, RIMSZA L, LEONARD J, KAMINSKI.. | 1 0.01 95.25 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.26 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.27 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.28 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.29 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 3 0.03 95.32 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.33 , MARTIN P, CHRISTOS P, CERCHIETTI L,.. | 1 0.01 95.34 , MIYAKE T, SAEKI I, ET AL. LAPAROSCO.. | 1 0.01 95.35 , NAKAYAMA N AND MOCHIDA S ACUTE HEPA.. | 1 0.01 95.36 , NAPIER E, SVOBODA J, NASTA S, MATO .. | 1 0.01 95.37 , NASTOUPIL L, DAVIS R, HAGEMEISTER F.. | 1 0.01 95.38 , NOVELLO S, SCHILLER J, HIRSH V, SEQ.. | 1 0.01 95.39 , O BRIEN T, GRAHAM J, HITCHCOCK A, L.. | 1 0.01 95.40 , OLIVEIRA A, FERREIRA P, RESENDE M, .. | 1 0.01 95.41 , O^BRIEN S, THOMAS D, SASAKI K, GARC.. | 1 0.01 95.42 , O^BRIEN T, GRAHAM J, HITCHCOCK A, L.. | 1 0.01 95.43 , O^BRIEN T, GRAHAM J, HITCHCOCK A, L.. | 3 0.03 95.46 , O^NEILL A, IMUS P, GUJAR S, SCHIFF .. | 1 0.01 95.47 , PATEL K, MALLAMPATHI S, DUOSE Y, NE.. | 1 0.01 95.48 , PATT Y, MURRAY-KREZAN C, HANSON J, .. | 1 0.01 95.49 , PETERSEN J, GSCHWANTLER M, CORNBERG.. | 1 0.01 95.50 , RAJWA P, PARADYSZ A AND BRYNIARSKI .. | 1 0.01 95.51 , STEINER N, WILLENBACHER W, CERCHION.. | 1 0.01 95.52 , SUTERA P, XU K, BERNARD M, BURTON S.. | 1 0.01 95.53 , TEDESCO H, BRIGIDO A, FELIPE C, HAN.. | 1 0.01 95.54 , TETSUO IITA, PYEONGTAEK PENG, DAYAN.. | 1 0.01 95.55 , THOMPSON D, BOCCIA R, MILETELLO G, .. | 1 0.01 95.56 , TOBINAI K, WAKABAYASHI M, MORISHIMA.. | 1 0.01 95.57 , TOYOKAWA T, OMOTE S, ET AL THE EFFI.. | 1 0.01 95.58 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 1 0.01 95.59 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 3 0.03 95.62 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 3 0.03 95.65 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 4 0.04 95.69 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 2 0.02 95.71 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 3 0.03 95.74 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 8 0.08 95.82 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 6 0.06 95.88 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 2 0.02 95.90 , WANG X, ROBINSON T, LINDLEY R, ARIM.. | 1 0.01 95.91 , WANG X, ROBINSON T, LINDLEY R, ZHOU.. | 1 0.01 95.92 . DYNAMIC CONTRAST-ENHANCED ULTRASONO.. | 1 0.01 95.93 1) ARELLANO AL, MARTIN M, MONERRIS M,.. | 1 0.01 95.94 ADAY AW, LEVY BD, LOSCALZO J, SAAVEND.. | 1 0.01 95.95 AFDHAL NH, BACON B, CURRY M, DIETERIC.. | 1 0.01 95.96 AGRAWAL V, CHAUDHARI S, SY A, DELATRE.. | 1 0.01 95.97 AGUIAR, FRANCISCA. OFF-LABEL USE OF R.. | 1 0.01 95.98 AL-ALOUL M, MILLER H, STOCKTON P, LED.. | 1 0.01 95.99 ALY ZA, ASHLEY JMP, GELLENS ME, GONZA.. | 1 0.01 96.00 AMINI M, ABDEGAH A, MOLAVI B, RADMARD.. | 1 0.01 96.01 AMOROSO L, VALTEAU-COUANET D, CASTEL .. | 1 0.01 96.02 ANIL H, TEKIN RT, ERZENCI A, HARMANCI.. | 1 0.01 96.03 ASADA Y, TSURUTA M, HASEGAWA H, ET AL.. | 1 0.01 96.04 AVCIN SL, POKORN M, KITANOVSKI L, PR.. | 1 0.01 96.05 AWORTWE C, MAKIWANE M, REUTER H, MULL.. | 1 0.01 96.06 BABAKINEJAD P, JAIN D, BHAT A AMD VAT.. | 1 0.01 96.07 BAKER, R.. FIRST EPISODE MANIA FOLLOW.. | 1 0.01 96.08 BARTKO J, ROSCHGER P, ZANDIEH S, BREH.. | 1 0.01 96.09 BARUAH A, GEORGE G, STRONGER JH. AN U.. | 1 0.01 96.10 BARUAH, A.. AN UNUSUAL CASE OF LOWER .. | 1 0.01 96.11 BEI KRITISCHEN NOTFALLEN AUF EIN ANTI.. | 1 0.01 96.12 BEINHARDT S, AL-ZOAIRY R, FREISSMUTH .. | 1 0.01 96.13 BENNETT C, BERGER J, SARTOR O, CARSON.. | 1 0.01 96.14 BERTHELOT E, LAVENU-BOMBLED C, OROSTE.. | 1 0.01 96.15 BINAGHI G, CONGIA D, COSSA S, MASSIDD.. | 1 0.01 96.16 BONETTA, A.. NEOADJUVANT CHEMOTHERAPY.. | 1 0.01 96.17 BORCHMANN P., EICHENAUER DA., PTUTSCH.. | 1 0.01 96.18 BOULTON J, PHYSICIAN; AMOS R, PHYSICI.. | 1 0.01 96.19 BRIGO F, PAGANI E, TEZZON F, MASI E, .. | 1 0.01 96.20 BROMLEY RL, MAWER GE, BRIGGS M, CHEYN.. | 1 0.01 96.21 BRUNNEMER E, W?LSCHER J, TENENBAUM S,.. | 1 0.01 96.22 BUCHHOLZ S, DAMMANN E, STADLER M, KRA.. | 1 0.01 96.23 BUCHHOLZ S, DAMMANN E, STADLER M, KRA.. | 1 0.01 96.24 BUI M, LE S, LE T AND BUI M. THE FIRS.. | 1 0.01 96.25 CANDIA RB, LAHARIE D, KATTAN ET, IR.. | 1 0.01 96.26 CANDIA RB, LAHARIE D, KATTAN ET, IR.. | 1 0.01 96.27 CANO-MOLLINEDO M, RODRIGUEZ DEL RIO P.. | 1 0.01 96.28 CARMO J, MARQUES SC, BISPO M, PINTO D.. | 1 0.01 96.29 CHANTEPIE, A.. FAILURE OF AMIODARONE .. | 1 0.01 96.30 CHEAH CK, VIJAYA SINGHAM N, GUN SC. A.. | 1 0.01 96.31 CHEN, C.. LOW-DOSE METHOTREXATE-INDUC.. | 1 0.01 96.32 CHEN, E.. A PHASE I STUDY OF OLAPARIB.. | 1 0.01 96.33 CLOWSE, M.. PREGNANCY OUTCOMES IN THE.. | 3 0.03 96.36 CLOWSE, M.. PREGNANCY OUTCOMES IN THE.. | 2 0.02 96.38 COLLINS P, VIJGEN S, DE PRIJCK B, BL?.. | 1 0.01 96.39 COLOVIC N, BOGDANOVIC A, VIRIJEVIC M,.. | 1 0.01 96.40 CORREA C, LUENGAS JP, HOWARD SC, VEIN.. | 1 0.01 96.41 COYNE JD, CAMPBELL F. MICROSCOPIC FEA.. | 1 0.01 96.42 DADPOUR B, ABBASPOUR H, POURZAHED A, .. | 1 0.01 96.43 DARBAN M, BAGHERI B. DRUG REACTION WI.. | 1 0.01 96.44 DAS BB, RAKHEJA D, LACELLE C, SEDLAK .. | 1 0.01 96.45 DASIC, G. SAFETY SIGNAL DETECTION AND.. | 1 0.01 96.46 DASIC, G.. SAFETY SIGNAL DETECTION AN.. | 5 0.05 96.51 DASIC, G.. SAFETY SIGNAL DETECTION AN.. | 2 0.02 96.53 DAVIS K, MORRISON C.. TICAGRELOR FOR .. | 1 0.01 96.54 DE OLIVEIRA W, BORSATO M, DABRONZO M,.. | 1 0.01 96.55 DE WITTE LD, DEKKER D, VERAART J, KRO.. | 1 0.01 96.56 DEJOU-BOUILLET L, BOURDEL N, SLIM K, .. | 1 0.01 96.57 DEL RIO-CASANOVA, L. VENLAFAXINE-INDU.. | 1 0.01 96.58 DERENZINI E, IACOBUCCI I, AGOSTINELLI.. | 1 0.01 96.59 DERENZINI, E.. THERAPEUTIC IMPLICATIO.. | 1 0.01 96.60 DESCOEUR J, PHILIBERT L, CHALARD K, A.. | 1 0.01 96.61 DESCOEUR J, PHILIBERT L, CHALARD K, A.. | 1 0.01 96.62 DESCOEUR J, PHILIBERT L, CHALARD K, E.. | 1 0.01 96.63 DI RUSSO, P.. PHENYTOIN-INDUCED RHABD.. | 1 0.01 96.64 DIA D, GUEYE MN, DIOUF G, DIALLO M, B.. | 1 0.01 96.65 DIENER H, ESCHENFELDER C, GROND M. RE.. | 1 0.01 96.66 DIENER H, KERMER P, ESCHENFELDER C, G.. | 1 0.01 96.67 DOI 10.1007/S00228-017-2275-6 LERTXUN.. | 1 0.01 96.68 DOI: 10.1210/JC.2016-2905 GRASEMANN C.. | 1 0.01 96.69 DOI: 10.3109/14397595.2015.1059008#. .. | 1 0.01 96.70 DOI: 10.5144/0256-4947.2018.09.01.143.. | 1 0.01 96.71 DOI:10.2515/THERAPIE/2015052#. CHARFI.. | 1 0.01 96.72 DOMINGO-ECHABURU S.. HICCUPS IN PARKI.. | 1 0.01 96.73 DUDEK C,SARANDRIA J. MULTIPLE UNUSUAL.. | 1 0.01 96.74 DUROCHER, J.. PROFOUND HYPERTHERMIA A.. | 1 0.01 96.75 EDWARDS G, ROMAN C, JITHOO R, MITRA B.. | 1 0.01 96.76 EDWARDS MH, MCCRAE FC, YOUNG-MIN SA.... | 1 0.01 96.77 ESHAGHI A, SHALHOUB S, ROSENFELD P, L.. | 1 0.01 96.78 ETZELSDORFER M.; EIRISCH G.; BECK-MAN.. | 1 0.01 96.79 EVERAGE N, PRADA C, LIU S, BALASHOV K.. | 1 0.01 96.80 F KENNEDY. MALFORMATION RISKS OF ANTI.. | 1 0.01 96.81 FERNANDEZ CV, MULLEN EA, EHRLICH PF, .. | 1 0.01 96.82 FERNANDEZ-FERREIRO, A.. SEROTONIN SYN.. | 1 0.01 96.83 FEY H, JOST M, GEISE AT, BERTSCH T, C.. | 1 0.01 96.84 FILIPPI L, PADRINI L, DANIOTTI M, AMA.. | 1 0.01 96.85 FISCHLER B, PRIFTAKIS P, SUNDIN M. SO.. | 1 0.01 96.86 FLINN I, THOMPSON D, BOCCIA R, MILETE.. | 1 0.01 96.87 FORSSBERG M, KLIMKOWSKA M AND MACHACZ.. | 1 0.01 96.88 FRENCH S, DUBOIS SG, HORN B, GRANGER .. | 1 0.01 96.89 FRENCH S, DUBOIS SG, HORN B, GRANGER .. | 1 0.01 96.90 FRETZAYAS A, LIAPI O, PAPADOPOULOU A,.. | 1 0.01 96.91 FRETZAYAS A, LIAPI O, PAPADOPOULOU A,.. | 2 0.02 96.93 FRITZSCHE FR, TUTIC M, OPITZ I, HUNZI.. | 1 0.01 96.94 FROST J, LOKKEN T, HELLAND A, NORDRUM.. | 1 0.01 96.95 FROST J, LOKKEN T, HELLAND A, NORDRUM.. | 1 0.01 96.96 FROST J, LOKKEN TN, HELLAND A, NORDRU.. | 1 0.01 96.97 FUJII K, KUNIHIRO M, KOSAKA M, HIRATA.. | 1 0.01 96.98 FUKUMORI T. RARE ADVERSE DRUG REACTIO.. | 1 0.01 96.99 G NILSSON. A. 37. GOT A COUGH MEDICIN.. | 1 0.01 97.00 GAGYOR I, BLEIDORN J, KOCHEN MM, SCHM.. | 1 0.01 97.01 GAMBACORTI PASSERINI, CARLO. LONG-TER.. | 3 0.03 97.04 GAMBACORTI-PASSERINI, C.. LONG-TERM E.. | 3 0.03 97.07 GAMBACORTI-PASSERINI, CARLO. LONG-TER.. | 1 0.01 97.08 GARG N, ALTOWAIJRI G, NESBIT G, GULTE.. | 1 0.01 97.09 GARZA-CHAPA, J.. COLD SUBCUTANEOUS AB.. | 1 0.01 97.10 GENDRON N, GAY J, LEMOINE M, ET AL. U.. | 1 0.01 97.11 GENDRON N, GAY J, LEMOINE M, GAUSSEM .. | 2 0.02 97.13 GENDRON N, GAY J, LEMOINE M, GAUSSEM .. | 1 0.01 97.14 GIESELBACH R, MULLER-HANSMA A, WIJBUR.. | 1 0.01 97.15 GILLISSEN MA, DE JONG G, LEVIE SE, YA.. | 1 0.01 97.16 GOUJON S. RISK OF CANCER IN CHILDREN .. | 1 0.01 97.17 GREBER A,WOLSKI R,HEINTZ M. HORNER^S .. | 1 0.01 97.18 HAAG L, HOFMANN J, KREDEL L, HOLZEM C.. | 1 0.01 97.19 HANSSON L, WINQVIST M, ASKLID A, ANDE.. | 1 0.01 97.20 HANSSON L, WINQVIST M, ASKLID A, ANDE.. | 1 0.01 97.21 HARADA M, ET AL.. BULLOUS PEMPHIGOID .. | 1 0.01 97.22 HARDEN CT, ELIASON F, BHALODIA S, CHU.. | 1 0.01 97.23 HARRISON AB, SUMNER M, SOBECKI J, CHR.. | 1 0.01 97.24 HASIJA RP, SILVERMAN E, CHO S, FUNG L.. | 1 0.01 97.25 HASIJA RP, SILVERMAN ED, CHO S, FUNG .. | 1 0.01 97.26 HASIJA RP, SILVERMAN ED, CHO S, FUNG .. | 1 0.01 97.27 HAYASHI S, MARUOKA S, TAKAHASHI N, HA.. | 1 0.01 97.28 HEROLD M. BIOREG: SUCCESSFUL BIOLOGIC.. | 1 0.01 97.29 HIDAKA N, TAGUCHI M. STUDY ON 6 CASES.. | 1 0.01 97.30 HIRAKAWA T. A CASE OF MALIGNANT TONGU.. | 1 0.01 97.31 HIROSE K, MIYAMOTO C, MATSUDATE Y, ET.. | 1 0.01 97.32 HIROTA Y, SAWADA T, SUWANAI H, IZUMID.. | 1 0.01 97.33 HLEYHEL M, GOUJON S, DELTEIL C, VASIL.. | 2 0.02 97.35 HUMAYUN Y, SANCHEZ P, NORRIS L, MONGA.. | 1 0.01 97.36 HUTSON, T.. AXITINIB VERSUS SORAFENIB.. | 1 0.01 97.37 IANNI, F.. GC-MS/MS DETECTS POTENTIA.. | 1 0.01 97.38 IBERRI DJ, KWONG B, STEVENS L, COUTR.. | 1 0.01 97.39 IIDA K., TAKAKU Y., AND OHTSURU H.. O.. | 1 0.01 97.40 IKEHARA K, UCHINO H, KAKUMAE Y, MIYAS.. | 1 0.01 97.41 IMAMOVIC, D.. CIPROFLOXACIN AS THE CA.. | 1 0.01 97.42 IMBULDENIYA, A.. BILATERAL ATYPICAL I.. | 1 0.01 97.43 INAGAKI TETSUJI, A CASE OF TUBULOINTE.. | 1 0.01 97.44 INOUE Y, DOI Y, ARISATO T, ET AL. THR.. | 1 0.01 97.45 ITO Y, FURUI Y, KAWAMURA M,TSURUMI Y,.. | 1 0.01 97.46 JAIN R, CHAN J D, ROGERS L, DELLIT T .. | 1 0.01 97.47 JALAEIAN, H.. ANAPHYLACTIC REACTION T.. | 1 0.01 97.48 JONES, N.. SEPSIS DURING IMMUNOSUPPRE.. | 1 0.01 97.49 JONSSON, B.. INJECTION OF CRUSHED TAB.. | 1 0.01 97.50 JORGENSEN JS, LANDSCHOFF LASSEN L, WE.. | 1 0.01 97.51 JOY K, DUBOIS S, GIBBONS C, HARGADON .. | 1 0.01 97.52 JOY K, DUBOIS S, GIBBONS C, HARGADON .. | 2 0.02 97.54 JUURLINK DN, GOMES T, GUTTMAN A, HEEL.. | 1 0.01 97.55 K L. | 1 0.01 97.56 KAICKER, J.. CO-INGESTION OF TRICYCLI.. | 1 0.01 97.57 KALKAN IH, DAGLI ?. SAFETY OF DRUGS U.. | 2 0.02 97.59 KALKAN IH, DAGLI U. SAFETY OF DRUGS U.. | 2 0.02 97.61 KAMEDA, T.. AXITINIB-INDUCED PNEUMATO.. | 1 0.01 97.62 KAPELIOS CJ, KARAMANAKOS G, LIATIS S,.. | 1 0.01 97.63 KAPELIOS, C.. RECURRENT EPISODES OF L.. | 2 0.02 97.65 KATAYAMA K, KUMAGAI R, ISONO M, FUJIH.. | 1 0.01 97.66 KATAYAMA K, KUMAGAI R, ISONO M, FUJIH.. | 1 0.01 97.67 KATO J, SATO Y, OHNUMA H, HIRAKAWA M,.. | 1 0.01 97.68 KATO K, YOSHIMI A, NOMURA T, NAKAO T,.. | 2 0.02 97.70 KEERTHANA BRATTIYA R, BHUVANESHWARI K.. | 1 0.01 97.71 KESHTKARI A, DEHGHANI S, HAGHIGHAT M,.. | 1 0.01 97.72 KHAN T, REDDY U. CONJUNCTIVAL PIGMENT.. | 1 0.01 97.73 KIMURA-TSUCHIYA R, SASAKI E, NAKAMURA.. | 1 0.01 97.74 KING, G.. A CASE OF SEVERE NSAID EXAC.. | 1 0.01 97.75 KLEINMANN JF, ARNAUD L, SAULEAU E, .. | 1 0.01 97.76 KOBAYASHI T, MATSUI HIROTO, YAMADA KE.. | 1 0.01 97.77 KOCA T, AKCAM M. IBUPROFEN-INDUCED DR.. | 1 0.01 97.78 KODALI S, BATHINI V, RAVA P, AND TIPI.. | 1 0.01 97.79 KOHATA N, WAKINO S, TOKUYAMA H, HAYAS.. | 1 0.01 97.80 KOJIC, M.. PLEURAL EMPYEMA CAUSED BY .. | 1 0.01 97.81 KOMASARA L, STEFANOWICZ J, BRYKS-LASZ.. | 1 0.01 97.82 KOMASARA L, STEFANOWICZ J, BRYKS-LASZ.. | 1 0.01 97.83 KOMORI K. A CASE OF FULMINANT HEPATIT.. | 1 0.01 97.84 KOPECKOVA K. NEW POSSIBILITIES OF TAR.. | 1 0.01 97.85 KOUWENBERG, I.C. ^DRESSED^ TO KILL: F.. | 1 0.01 97.86 KOVACEVIC A, SCHWAHN B, SCHUSTER A. H.. | 1 0.01 97.87 KOWALZICK L,EICKENSCHEIDT L. LONG TER.. | 1 0.01 97.88 KRATI K, CHERQUAOUI H. REACTIVATION O.. | 1 0.01 97.89 KRUM H, SCHLAICH PM, BOHM M, MAHFOUD .. | 1 0.01 97.90 KUBO, H.. IS YOLK SAC TUMOR RELATED T.. | 1 0.01 97.91 KWELLA N. THE IMPACT OF CALCINEURIN I.. | 1 0.01 97.92 LAN YW, HSIEH JW. BILATERAL ACUTE ANG.. | 1 0.01 97.93 LANMAN TA, BAKAR D, BADDERS NM, BURKE.. | 1 0.01 97.94 LE VAILLANT, J. ACETAMINOPHEN (PARACE.. | 1 0.01 97.95 LEANTE-CASTELLANOS JL, ZAMORA-GIMENO .. | 1 0.01 97.96 LEDINGHAM D.. HEYDE^S SYNDROME: EXPLO.. | 1 0.01 97.97 LITOVITZ T. 2003 ANNUAL REPORT OF THE.. | 1 0.01 97.98 LIVERI K, CONSTANTINOU MA, AFXENTIOU .. | 1 0.01 97.99 LOBO N,EJIOFOR K,THURAIRAJA R,KHAN S... | 1 0.01 98.00 LOGAN BK, LOWRIE KJ, TURRI JL, YEAKEL.. | 1 0.01 98.01 LONG TERM TREATMENT OF PSORIASIS WITH.. | 1 0.01 98.02 LOOSE L. | 1 0.01 98.03 LUSETTI M, LICATA M, SILINGARDI E, BO.. | 1 0.01 98.04 M. H, S. G, C. D, A. V, S. L, L S, ET.. | 1 0.01 98.05 M.BAHLOULA, CHAARIA A, DAMMAKA H, MED.. | 1 0.01 98.06 MAENG CH, PARK JS, LEE SA, KIM DH, YU.. | 1 0.01 98.07 MAFRICI A, MAURI F, MAGGIONI A P, FRA.. | 1 0.01 98.08 MAHIL S, MARTIN B, CREAMER D, SMITH C.. | 1 0.01 98.09 MAKITA, H.. A CASE REPORT OF COAGULAT.. | 1 0.01 98.10 MARTIN A, REDONDO A. LENALIDOMIDE IN .. | 1 0.01 98.11 MARUYAMA S. EXAMINATION OF CASES PRES.. | 1 0.01 98.12 MARUYAMA Y, IKEDA Y, YOKOI N, MORI K,.. | 1 0.01 98.13 MASATO H, WADA Y, KUROSAWA Y, YAMAMOT.. | 1 0.01 98.14 MASAYUKI,KANEKO. A CASE OF MALIGNANT .. | 1 0.01 98.15 MASKELL, P.. SEVEN FATALITIES ASSOCIA.. | 1 0.01 98.16 MASUDA, N.. PALBOCICLIB IN COMBINATIO.. | 1 0.01 98.17 MCINTYRE I, MALLETT P, STOLBERG S, HA.. | 1 0.01 98.18 MCINTYRE IM, MALLETT P, STOLBERG S, M.. | 1 0.01 98.19 MCINTYRE, I.. STRIKING INCREASES IN P.. | 1 0.01 98.20 MCKINNEY, C.. LIVEDOID DERMATITIS (NI.. | 1 0.01 98.21 MEISER, BRUNO. DE-NOVO CALCINEURIN-IN.. | 1 0.01 98.22 MICHELS G, KOCHANEK M, PFISTER R. LIF.. | 1 0.01 98.23 MICHELS G, KOCHANEK M, PFISTER R... L.. | 1 0.01 98.24 MICHELS G,KOCHANEK M,PFISTER R. LIFE-.. | 1 0.01 98.25 MICHELS, G.. LIFE-THREATENING CARDIAC.. | 1 0.01 98.26 MICHELS, G.. LIFE-THREATENING CARDIAC.. | 1 0.01 98.27 MICHELS, G.. LIFE-THREATENING CARDIAC.. | 1 0.01 98.28 MIYAKOSHI T, TSUTSUMISAKA H, ET AL. A.. | 1 0.01 98.29 MIYATA T. AN ATTEMPT TO DECREASE HEAL.. | 1 0.01 98.30 MIZUKAMI T, TANIGUCHI, [KUDAKORE] [DA.. | 1 0.01 98.31 MOEBUS V, NOEDING S, LADDA E, KLARE P.. | 1 0.01 98.32 MONTAGUE AJ, LEE SC, LINTNER CP, FUJI.. | 1 0.01 98.33 MONTAZERI, N.. PYOMYOSITIS CAUSING TE.. | 1 0.01 98.34 MORIYA, C.. TOXIC EPIDERMAL NECROLYSI.. | 1 0.01 98.35 MOTOKI TAKAMURO, KIMURA. S, HASEYAMA... | 1 0.01 98.36 MOWRY, J.. 2014 ANNUAL REPORT OF THE .. | 1 0.01 98.37 MUPPIDI MR, GRIFFITHS EA, THOMPSON JE.. | 1 0.01 98.38 MUPPIDI MR, GRIFFITHS EA, THOMPSON JE.. | 1 0.01 98.39 MURATA K, OKAMURA SHU, OWADA YOSHIYUK.. | 1 0.01 98.40 MUSSO M, GIANNELLA M, ANTONINI M, BOR.. | 1 0.01 98.41 MUSSO M, GIANNELLA M, ANTONINI M, BOR.. | 1 0.01 98.42 M^KADA H, PERAZZO H, MUNTEANU M, NGO.. | 1 0.01 98.43 M^KADA H, PERAZZO H, MUNTEANU M, NGO .. | 1 0.01 98.44 N?HNEN V. STEVENS-JOHNSON SYNDROME/TO.. | 1 0.01 98.45 NAGAMINE T. LITHIUM INTOXICATION ASSO.. | 1 0.01 98.46 NAGASE S.. CURRENT STATUS OF T790M GE.. | 1 0.01 98.47 NAKAMURA Y, KAMEI T, SHINAGAWA M, SAK.. | 1 0.01 98.48 NAKAO Y.. A CASE OF LUNG DISEASE DURI.. | 1 0.01 98.49 NATSUMEDA M, FUJIMORI M, TAKASUGI K, .. | 1 0.01 98.50 NEDAHL M, JOHANSEN SS, LINNET K ET.AL.. | 1 0.01 98.51 NEDAHL M, JOHANSEN SS, LINNET K. REFE.. | 1 0.01 98.52 NEIL L. BERINSTEIN. PROLONGED CLINICA.. | 1 0.01 98.53 NGUYEN PVQ, SPINELLI C. PRESCRIBING C.. | 1 0.01 98.54 NICOLAS G, ALBERT T, GREGOIRE L, ERIC.. | 1 0.01 98.55 NICOLAS G, ALBERT T, GREGOIRE L, ERIC.. | 1 0.01 98.56 NISHI T. A CASE OF A RUPTURE OF THE C.. | 1 0.01 98.57 NISHIKAWA K, TSUBURAYA A, YOSHIKAWA T.. | 1 0.01 98.58 NOMOTO H, MATSUBARA Y, ICHIMIYA Y, AR.. | 1 0.01 98.59 NOORTJE THIELEN, BRONNO VAN DER HOLT,.. | 1 0.01 98.60 NORMAN H, ELFINEH M, BEIJER E, CASSWA.. | 1 0.01 98.61 NORMAN H, ELFINEH M, BEIJER E, ET AL... | 1 0.01 98.62 OFLAZOGLU, U.. CASE REPORT OF A RENAL.. | 1 0.01 98.63 OKUMURA, K.. A CASE OF CEFTRIAXONE-AS.. | 1 0.01 98.64 ONEMORI Y.,ET AL. A CASE OF DRUG-INDU.. | 1 0.01 98.65 ONUIGBO MAC, AGBASI N. THE IGNORED RO.. | 1 0.01 98.66 ONUIGBO MAC, ET AL.. THE IGNORED ROLE.. | 1 0.01 98.67 OUERGHI, K.. NOREPINEPHRINE INDUCED A.. | 1 0.01 98.68 OZAKI K, ET AL.. TWO CASES OF SUSPECT.. | 1 0.01 98.69 OZAWA A, HASEGAWA M, NAGAYAMA N, MATS.. | 1 0.01 98.70 PADHYE B, DALLA-POZZA L, LITTLE D, MU.. | 1 0.01 98.71 PADHYE B, DALLA-POZZA L, LITTLE D, MU.. | 1 0.01 98.72 PARK J, SUN K, CHO J, ET AL. A CASE O.. | 1 0.01 98.73 PASALA S, ALAN B, FIELD O. LONG-TERM .. | 1 0.01 98.74 PASALA S, ALAN B, FIELD O. LONG-TERM .. | 1 0.01 98.75 PASINI A, PITZIANTI M, BARATTA A, MOA.. | 1 0.01 98.76 PENIT A, BEMER P, BESSON J, CAZET L, .. | 1 0.01 98.77 PENIT A, BEMER P, BESSON J, CAZET L, .. | 1 0.01 98.78 PFEUFFER S, BEUKER C, RUCK T, LENZE F.. | 2 0.02 98.80 PHARMACOLOGY AND THERAPEUT. 2014 APR;.. | 1 0.01 98.81 PILGRIM S. DIAPHRAGM DISEASE AND SMAL.. | 1 0.01 98.82 PLESNER T. DARATUMUMAB IN COMBINATION.. | 1 0.01 98.83 POGLIANI D, POZZI A, LAUDI C, RIMOLDI.. | 1 0.01 98.84 POGLIANI D,POZZI A,LAUDI C,RIMOLDI L,.. | 1 0.01 98.85 POGLIANI, D.. NONCONVULSIVE STATUS EP.. | 1 0.01 98.86 POPE R, ANGELA K.. DARUNAVIR FOR USE .. | 1 0.01 98.87 POPE R, KASHUBA A. DARUNAVIR FOR USE .. | 2 0.02 98.89 POPE R, KASHUBA A.. DARUNAVIR FOR USE.. | 1 0.01 98.90 POPE R, KASHUBA A.. DARUNAVIR FOR USE.. | 2 0.02 98.92 POTTHOFF K, NUSCH A, SOLING U, HANSEN.. | 1 0.01 98.93 PRIOU, P.. DRUG-INDUCED PNEUMONITIS I.. | 1 0.01 98.94 PRIVACY P, , BAILLY F, MARIANI L, PEN.. | 1 0.01 98.95 PRIVACY, SCHULZE A, REBBER E, WIEBE S.. | 1 0.01 98.96 PROENCA P ET AL.. UPLCMS/ MS DETERMIN.. | 1 0.01 98.97 PROENCA P, FRANCO JM, MUSTRA C, MONTE.. | 1 0.01 98.98 QUIROGA B, BASTERRECHEA MA, FERN?NDEZ.. | 1 0.01 98.99 RE A, CATTANEO C, CASARI S, GINI G, M.. | 1 0.01 99.00 RE A, CATTANEO C, CASARI S, GINI G, M.. | 2 0.02 99.02 REINA, D.. VISCERAL LEISHMANIASIS IN .. | 1 0.01 99.03 REV NEUROL 2015; 60(10): 475-477; R?O.. | 1 0.01 99.04 RF ROSE. AACQUIRED PORT-WINE STAIN OC.. | 1 0.01 99.05 ROBERT PJ, ANGELA K.. DARUNAVIR FOR U.. | 1 0.01 99.06 ROBERT PJ, ANGELA K.. DARUNAVIR FOR U.. | 1 0.01 99.07 ROBERT POPE JR AND ANGELA KASHUBA.. D.. | 2 0.02 99.09 ROCCI E, PARK K, HUTCHENS K, WINTERFI.. | 1 0.01 99.10 ROY B, MASSIE F. THE TIPPING POINT: M.. | 1 0.01 99.11 S. CHANTEPIE. DASATINIB- RELATED PNEU.. | 1 0.01 99.12 SAEED, N.. SALMONELLA PNEUMONIA COMPL.. | 1 0.01 99.13 SAITOU M, SUZUKI T, NIITSUMA K. PULMO.. | 2 0.02 99.15 SANOMURA Y, TANAKA S, OKA S, CHAYAMA .. | 1 0.01 99.16 SASAKI K, KISHIMOTO T, MIHARA S., ET .. | 1 0.01 99.17 SATO J, MAKITA N, MANAKA K, ARAI M, I.. | 1 0.01 99.18 SBRANA, F.. DABIGATRAN MALABSORPTION .. | 1 0.01 99.19 SCHARL, A.. FATIGUE FOLLOWING ONCOLOG.. | 1 0.01 99.20 SCHERL T, ET AL.. BUSPIRONE/DOXEPIN/R.. | 1 0.01 99.21 SCHERL TA, LANGGUTH B, KREUZER PM. HY.. | 1 0.01 99.22 SCHERL TA, LANGGUTH B, KREUZER PM. HY.. | 1 0.01 99.23 SEON KA; TSENG SH; WENG CC; CHEN Y.. .. | 1 0.01 99.24 SETH A, PANDIT S, HOSSEINI CP, SHEHZA.. | 1 0.01 99.25 SHARMA P, KRISHNAMOORTHY P. COLON ISC.. | 1 0.01 99.26 SHEREMATA W, DELGADO SR, RAMMOHAN KW... | 1 0.01 99.27 SHEREMATA W, DELGADO SR, RAMMOHAN KW... | 1 0.01 99.28 SILVER AJ, PATEL HN, OKWUOSA T. HYPOT.. | 1 0.01 99.29 SINDHI V. PROGRESSION OF PROGRESSIVE .. | 1 0.01 99.30 SLATER S, MCKAY S, MACLAREN V, HICKS .. | 1 0.01 99.31 SOUCHET L, LEVY V, OUZEGDOUH M, TAMBU.. | 1 0.01 99.32 SPIELMANN L, MESSER L, MOREAU P, ETIE.. | 1 0.01 99.33 STANFORD, F.. POSTERIOR REVERSIBLE EN.. | 1 0.01 99.34 STANFORD, F.. POSTERIOR REVERSIBLE EN.. | 1 0.01 99.35 STEINBACHER D, TRAVIESO R, WU R, WU R.. | 1 0.01 99.36 STEPANKOVA L. OPRAVDU TO NESLO JINAK?.. | 1 0.01 99.37 STEPHAN JL. RISK OF CANCER IN CHILDRE.. | 2 0.02 99.39 SUEHIRO T, SHIBATA H, HONDA T, OZAWA .. | 1 0.01 99.40 SULLO MG, PERRI D, SIBILIO M, RAFANIE.. | 1 0.01 99.41 TAKAHASHI K, HANEDA S, TOKUMURA H, ET.. | 1 0.01 99.42 TANAKA, K. THE EFFECTS OF MITIGLINIDE.. | 1 0.01 99.43 TANAKA,K. THE EFFECTS OF MITIGLINIDE .. | 1 0.01 99.44 TEMPFER CB, CELIK I, SOLASS W, BUERKL.. | 1 0.01 99.45 TEMPFER CB, CELIK I, SOLASS W, BUERKL.. | 2 0.02 99.47 TEMPFER CB, CELIK I, SOLASS W, BUERKL.. | 1 0.01 99.48 TERADA S, YOSHIOKA H, KINOSHITA M, HA.. | 1 0.01 99.49 TORRETTA S, GAFFURI M, RECALCATI S, M.. | 1 0.01 99.50 TOUZEAU C, MOREAU P. HOW I TREAT EXTR.. | 1 0.01 99.51 TRIZULJAK J. SUCCESSFUL IBRUTINIB TRE.. | 1 0.01 99.52 TSATIRIS K, DELIGIANNIS G, PLAKIAS S,.. | 1 0.01 99.53 TZOUVELEKIS A, NTOLIOS P, KARAMPITSAK.. | 1 0.01 99.54 UNKNOWN. UNKNOWN. UNKNOWN. | 1 0.01 99.55 VALKOVA V. THE EFFECT OF IBRUTINIB TR.. | 1 0.01 99.56 VALLERSNES. ADOLESCENT WITH RESPIRATO.. | 1 0.01 99.57 VAN DE LAARSCHOT D. PAMIDRONIC ACID/R.. | 1 0.01 99.58 VAN NGUYEN, J.. HOW COMMON IS THE GRO.. | 4 0.04 99.62 VANDAMME M, PAUWELS W, BLEECKER JD. A.. | 1 0.01 99.63 VAUGHN P, SOLIK MM, BAGGA S, PADANIL.. | 1 0.01 99.64 VENKATANARASIMHA ET AL N. SUBTROCHANT.. | 1 0.01 99.65 VENKATANARASIMHA N. SUBTROCHANTERIC F.. | 1 0.01 99.66 VENTRE MB, DONADONI G, RE A, SPINA M,.. | 1 0.01 99.67 VENTRE MB, DONADONI G, RE A, SPINA M,.. | 1 0.01 99.68 VENTRIGLIA J, LATERZA M, SAVASTANO B,.. | 1 0.01 99.69 VIARD T. INTOXICATION ? L^ESCITALOPRA.. | 1 0.01 99.70 VICKERY S, MCCLAIN D, WARGO KA. SUCCE.. | 1 0.01 99.71 VOIGT S, HOFMANN J, EDELMANN A, SAUER.. | 1 0.01 99.72 WALLACE, K.. SUBTHERAPEUTIC VORICONAZ.. | 1 0.01 99.73 WANATABE Y, YOSHII M, ABE T. A CASE O.. | 1 0.01 99.74 WANG B, ABBOTT L, CHILDS K, TAYLOR C,.. | 1 0.01 99.75 WANG L,CHEN R, TIAN F, WANG W, WANG L.. | 1 0.01 99.76 WARSZAWSKI J. OF CANCER IN CHILDREN P.. | 2 0.02 99.78 WASSEF N, KHAN N, MUNIR S. QUETIAPINE.. | 1 0.01 99.79 WATANABE E. SUCCESSFUL TOCILIZUMAB TH.. | 1 0.01 99.80 WEINBERG, R.. VENOARTERIAL EXTRACORPO.. | 1 0.01 99.81 WESTERGREN T, HJELMELAND K, KRISTOFFE.. | 1 0.01 99.82 WILLIAMS M, HONG F, GASCOYNE R, WAGNE.. | 1 0.01 99.83 WILLIS ED, WOODWARD M, BROWN E, POPMI.. | 1 0.01 99.84 WINTHROP, K.. THE EFFECTIVENESS OF ZO.. | 1 0.01 99.85 WOOD D, MONAGHAN J, STREETE P, DARGAN.. | 1 0.01 99.86 YANG BK, YOU JS, JOO YS, CHUNG SP, LE.. | 1 0.01 99.87 YAO D J, SADASHIV S, SAHOVIC E A, KHA.. | 1 0.01 99.88 YAROVOY AA, USHAKOVA TL, GORSHKOV IM,.. | 1 0.01 99.89 YASHIRO M, MATSUDA N, SAITO K, SHIOYA.. | 1 0.01 99.90 YOKOMIZO N, KURITA A, TANIGUCHI T.. T.. | 1 0.01 99.91 YOSHIMURA Y, NAKAHARAI K AND TACHIKAW.. | 1 0.01 99.92 YU M, CHUA J. VIRUS-ASSOCIATED HAEMOP.. | 1 0.01 99.93 YU, A.. OCCUPATIONAL AIRBORNE CONTACT.. | 1 0.01 99.94 ZACHARY MCCORMICK, SAMUEL K. CHU, GEO.. | 1 0.01 99.95 ZAFFANELLO M, BRUGNARA M, ANGELI S, C.. | 1 0.01 99.96 ZAWAR SV, MAHADIK S. CORNEAL DEPOSIT .. | 1 0.01 99.97 ZAWAR SV, MAHADIK S. CORNEAL DEPOSIT .. | 2 0.02 99.99 ZHANG H, LIU Z, ZHOU M, LIU Z, CHEN J.. | 1 0.01 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 19 Jun 2018